

Breaking Ground in Sarcoma Imaging: The Rise of FDG PET-CT as a Paradigm Shift


Dr. Muntaha Fatima Rana¹, Dr. Sana Munir Gill¹, Dr. Aamna Hassan¹.

¹Shaukat Khanum Memorial Cancer Hospital and Research Centre, Nuclear Medicine Department, Lahore, Pakistan.


OBJECTIVE

- Sarcoma is a relatively rare malignancy.
- Management is complex, and disease extent is the key factor in guiding appropriate therapy planning.
- NCCN guidelines recommend PET or CT for regional nodal metastases in angiosarcoma, clear cell sarcoma, rhabdomyosarcoma, epithelioid and synovial sarcoma.
- FDG PET-CT is a non-invasive imaging modality based on glucose metabolism.
- Increased glucose metabolism shows correlation with high grade nature and poor survival in soft tissue sarcomas.
- The study evaluates the role of PET-CT in staging/restaging of sarcomas and to find association of SUVmax with survival.

SITE OF PRIMARY TUMOR (%)



REASON FOR PET-CT




Materials & Methods

- Retrospective Analysis
- February 2022 to December 2024
- 197 PET/CT scans of 145 patients analyzed
- Parameters reviews
 - Age
 - Gender
 - Histopathology
 - Reason for PET-CT
 - Primary site
 - Metastatic sites
 - SUVmax of Primary site
 - Last follow up
- Analysis of SUVmax and survival using SPSS


RESULTS

- Most common histopathological type
 - Ewing sarcoma
 - Osteosarcoma
 - Leiomyosarcoma
- Age Range 5-75 years
- Gender distribution 52% males; 48% females
- PET-CT detected
- Primary site:
 - Primary/residual or recurrent disease 40.6% ; SUVmax range 6.7-21
 - Mild primary site uptake 6.1%
 - No uptake in primary 53.3%
- Nodal disease 30.5%
- Distant metastases
 - Lung 22.9%
 - Osseous/Marrow 15.2%
 - Visceral 23.8%
- PET-CT changed management : 15.2%

ANALYSIS OF SUVmax OF PRIMARY SITE WITH SURVIVAL



Kaplan-Meier analysis showed significantly poorer survival in patients with SUV >10 compared to SUV ≤10 (log-rank $\chi^2=4.38$, $p=0.036$).



CASES

CONCLUSION

PET-CT plays a vital role in staging and restaging sarcomas, with significant impact on detecting primary and metastatic disease and altering management.

High primary tumor SUV (>10) is associated with poorer survival, highlighting its prognostic value.

